期刊文献+

奥曲肽及其类似物用于肿瘤治疗的进展 被引量:9

Advances in tumor treatment with labeled somatostatin analogues
暂未订购
导出
摘要 简单综述90Y鄄奥曲肽、177Lu鄄奥曲肽在肿瘤治疗中的应用价值。对奥曲肽治疗的原理、在肿瘤及正常组织中的分布、对肾脏功能的影响和保护剂的应用进行介绍,主要治疗的病种包括不摄取131I的分化型甲状腺癌转移灶、Hurthle细胞甲状腺癌、甲状腺髓样癌、来自胃肠胰的神经内分泌肿瘤、小细胞癌、嗜铬细胞瘤等。对应用适合的剂量和未来新的可能用于临床治疗的放射肽和发展方向加以综述。 The values of 90Y-octreotide and 177Lu-octreotate in tumor treatment were briefly reviewed.The rationale of clinincal applications, the distribution of radiopeptide in tumor and nomal tissues and appli-cation of renal protective agents were reviewed as well. Tumor with potential therapeutic responses are many such as non-iodide avid cancer of thyroid gland, Hurthle cell thyroid cancer, medullary thyroid cancer, neuroendo-gastro-entero-pancreatic(GEP)tumor, small cell l cancer, carcinoid tumors and pheochromocytoma. The current state of clinical use of radiopeptide for therapy of tumors, the development of new compounds and future development, the dosage of radiopeptide for tumor treatment with well tolerated and remarkable clinical benefit were presented.
出处 《国外医学(放射医学核医学分册)》 2005年第2期79-84,共6页 Foreign Medical Sciences(Section of Radiation Medicine and Nuclear Medicine)
关键词 生长抑素 奥曲肽 分化型甲状腺癌 Hurthle细胞甲状腺癌 甲状腺髓样癌:胃肠 胰神经内分泌肿瘤 小细胞癌 嗜铬细胞瘤 somatostatin octreotide differentiated thyroid cancer Hurthle cell thyroid cancer medullary thyroid cancer gastro-entero-pancreatic tumor small cell cancer pheochromocytoma
  • 相关文献

参考文献35

  • 1Boerman O C, Oyen W J G, Corstens F H M. Between the scylla and charybdis of peptide radionuclide therapy:hitting the tumor and saving the kidney[J]. Eur J Nucl Med, 2001, 28:1447-1449.
  • 2Forssell-Aronsson E, Bernhardt P, Nilsson O, et al. Biodistribution data from 100 patients iv. injected with 111In-DTPA-D-pheloctreotide [J]. Acta Oncol, 2004, 43(5): 436-442.
  • 3Bushnell D, Menda Y, O' Dorisio T, et al. Effect of intravenous amino acid administration with Y-90 DOTA-Phe1-Tyr3-octreotide (SMT487[Octreo TherTM])treatment[J]. Cancer Biother Radiopharm,2004, 19(1): 35-41.
  • 4Pauwels S, Barone R, Walrand S, et al. Practical dosimetry of peptide receptor radionuclide therapy with 90Y-labeled somatostatin analogs[J]. J Nucl Med, 2005, 46(1 suppl): 92S-98S.
  • 5Moll S, Nickeleit V, Mueller-Brand J, et al. A new cause of renal thrombotic microangiopathy: Yttrium-90-DOTATOC internal radiotherapy[J]. Am J kidney Dis, 2001,37(4): 847-851.
  • 6Bodei L, Cremonesi M, Zoboli S, et al. Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion, a phase Ⅰ study[J]. Eur J Nucl Med Mol Imaging, 2003,30(2): 207-216.
  • 7Rolleman E J, Valkema R, de Jong M, et al. Safe and effective inhibition of renal uptake of radiolabelled octreotidc by a combination of lysine and arginine[J]. Eur J Nucl Med Mol Imaging, 2003, 30(1):9-15.
  • 8Barone R, Pauwels S, De Camps J, et al. Metabolic effects of amino acid solutions infused for renal protection during therapy with radiolabelled somatostatin analogs[J]. Nephrol Dial Transplant, 2004, 19(9): 2275-2281.
  • 9Barone R, Borson-Chazot F, Valkema R, et al. Patient-specific dosimetry in predicting renal toxicity with 90Y-DOTATOC: relevence of kidney volume and dose rate in finding a dose-effect relationship [J]. J Nucl Med, 2005, 46(lsuppl): 99s-106s.
  • 10Gabriel M, Froehlich F, Decristoforo C, et al. EDDA/HYNIC-TOC and 18F-FDG in thyroid cancer patients with negative 131I whole body scan[J]. Eur J Nucl Med Mol Imaging, 2004, 31(3): 330-341.

同被引文献165

引证文献9

二级引证文献33

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部